Viking Therapeutics Highlights Clinical Data From Vk2735 Obesity Program At Obesityweek
Nov 15 (Reuters) - Viking Therapeutics, Inc. VKTX.O:
VIKING THERAPEUTICS HIGHLIGHTS CLINICAL DATA FROM VK2735 OBESITY PROGRAM AT OBESITYWEEK® 2026
VIKING THERAPEUTICS - VK2735 TREATMENT LED TO IMPROVEMENT IN MULTIPLE CARDIOMETABOLIC MARKERS
VIKING THERAPEUTICS - 74% OF PARTICIPANTS RECEIVING VK2735 IMPROVED BMI CATEGORY AFTER 13 WEEKS
Further company coverage: VKTX.O